Trial Profile

A phase 3 long-term extension trial to evaluate durability and maintenance of response and long-term safety

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ESK-001 (Primary)
Indications Plaque psoriasis
Focus Adverse reactions; Therapeutic Use
Acronyms ONWARD 3
Sponsors Alumis

Most Recent Events

28 Feb 2025 According to an an Alumis media release, topline data from its pivotal Phase 3 ONWARD clinical program of ESK-001 for the treatment of moderate-to-severe PsO is expected in the first quarter of 2026.
13 Nov 2024 According to an an Alumis media release, company looks forward to reporting Topline results are anticipated in the first half of 2026
27 Sep 2024 According to an an Alumis media release, company looks forward to reporting the full 52-week OLE data in the first half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com